During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

AbbVie (NYSE:ABBV)

  • Dividend Yield: 3.08%
  • Piper Sandler analyst David Amsellem maintained an Overweight rating and raised the price target from $294 to $298 on May 14, 2026. This analyst has an accuracy rate of 79%.
  • Guggenheim analyst Vamil Divan maintained a Buy rating with a price target of $249 on May 1, 2026. This analyst has an accuracy rate of 76%
  • Recent News: On Friday, AbbVie highlighted long-term safety and efficacy of fixed-duration venetoclax-obinutuzumab in CLL14 trial after 9.2-year follow-up.
  • Benzinga Pro’s real-time newsfeed alerted to latest ABBV news.

Medtronic PLC (NYSE:MDT)

  • Dividend Yield: 3.59%
  • UBS analyst Priya Sachdeva maintained a Neutral rating and cut the price target from $90 to $85 on June 4, 2026. This analyst has an accuracy rate of 66%.
  • TD Cowen analyst Joshua Jennings maintained a Buy rating with a price target of $119 on June 4, 2026. This analyst has an accuracy rate of 57%
  • Recent News: On June 3, Medtronic posted upbeat quarterly results.
  • Benzinga Pro's real-time newsfeed alerted to latest MDT news

GSK plc (NYSE:GSK)

  • Dividend Yield: 3.41%
  • Barclays analyst James Gordon downgraded the stock from Equal-Weight to Underweight on Jan. 6, 2026. This analyst has an accuracy rate of 68%
  • Jeffries analyst Michael Leuchten upgraded the stock from Hold to Buy on Oct. 27, 2025. This analyst has an accuracy rate of 64%.
  • Recent News: On June 9, GSK agreed to acquire Boston-based biotech firm Nuvalent, Inc. (NASDAQ:NUVL) for $10.6 billion in cash as the British drugmaker seeks to strengthen its lung cancer portfolio.
  • Benzinga Pro’s real-time newsfeed alerted to latest GSK news

Photo via Shutterstock